| Year |
Citation |
Score |
| 2024 |
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, et al. Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood. PMID 39133921 DOI: 10.1182/blood.2024024944 |
0.314 |
|
| 2024 |
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, et al. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clinical Lymphoma, Myeloma & Leukemia. PMID 38378362 DOI: 10.1016/j.clml.2024.01.007 |
0.365 |
|
| 2024 |
Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American Journal of Hematology. PMID 38343151 DOI: 10.1002/ajh.27246 |
0.324 |
|
| 2023 |
Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, ... ... Jonas BA, et al. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leukemia & Lymphoma. 1-9. PMID 37801340 DOI: 10.1080/10428194.2023.2264426 |
0.35 |
|
| 2023 |
Pervitsky V, Guglielmo J, Moskoff B, Kneen R, Leija C, Sawicky D, Krackeler ML, Jonas BA, Beechinor R. Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 31: 224. PMID 36941508 DOI: 10.1007/s00520-023-07664-z |
0.355 |
|
| 2023 |
de Botton S, Fenaux P, Yee KWL, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove CS, Jonas BA, Khwaja A, Legrand O, Peterlin P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances. PMID 36724515 DOI: 10.1182/bloodadvances.2022009411 |
0.336 |
|
| 2022 |
Jonas BA, Wei AH, Recher C, DiNardo CD, Jang JH, Pratz K, Panayiotidis P, Montesinos P, Yeh SP, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology. PMID 35567776 DOI: 10.1002/ajh.26600 |
0.325 |
|
| 2021 |
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, et al. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101546. PMID 34910556 DOI: 10.1200/JCO.21.01546 |
0.383 |
|
| 2021 |
DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. PMID 34543383 DOI: 10.1182/blood.2021010721 |
0.335 |
|
| 2021 |
Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Review of Hematology. 14: 407-417. PMID 34076549 DOI: 10.1080/17474086.2021.1938533 |
0.386 |
|
| 2021 |
Othman TA, Azenkot T, Moskoff BN, Tenold ME, Jonas BA. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. Future Oncology (London, England). PMID 34024158 DOI: 10.2217/fon-2021-0262 |
0.351 |
|
| 2021 |
Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, Popovic R, Modi DA, Joshi RH, Wolff JE, Jonas BA. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer. PMID 33934351 DOI: 10.1002/cncr.33590 |
0.306 |
|
| 2021 |
Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Frontiers in Oncology. 11: 649209. PMID 33777810 DOI: 10.3389/fonc.2021.649209 |
0.416 |
|
| 2021 |
Othman T, Moskoff B, Tenold M, Azenkot T, Krackeler M, Fisch SC, Potter LA, Kaesberg PR, Welborn J, Wun T, Esteghamat N, Hoeg RT, Rosenberg AS, Abedi M, Tuscano J, ... Jonas BA, et al. A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Blood. 138: 4394-4394. DOI: 10.1182/blood-2021-149276 |
0.349 |
|
| 2021 |
Potter LA, Galkin M, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Blood. 138: 2352-2352. DOI: 10.1182/blood-2021-147349 |
0.355 |
|
| 2020 |
Chang Muñoz M, Murphy JA, Wolff JE, Jonas BA. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Reports in Hematology. 2020: 8830123. PMID 33381331 DOI: 10.1155/2020/8830123 |
0.4 |
|
| 2020 |
Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study. American Journal of Hematology. PMID 33119898 DOI: 10.1002/ajh.26039 |
0.326 |
|
| 2020 |
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. The New England Journal of Medicine. 383: 617-629. PMID 32786187 DOI: 10.1056/Nejmoa2012971 |
0.32 |
|
| 2020 |
Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clinical Lymphoma, Myeloma & Leukemia. PMID 32171691 DOI: 10.1016/j.clml.2020.02.006 |
0.301 |
|
| 2020 |
Jonas BA, Dinardo CD, Pratz K, Wei A, Hong W, Chyla B, Duan Y, Potluri J, Werner M, Pollyea DA. Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia. Journal of Clinical Oncology. 38: 7531-7531. DOI: 10.1200/jco.2020.38.15_suppl.7531 |
0.304 |
|
| 2020 |
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Döhner H, Fenaux P, Recher C, Konopleva M, Fiedler W, Koller E, Havelange V, Schuh AC, Esteve J, et al. AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A Clinical Lymphoma Myeloma and Leukemia. 20: S179. DOI: 10.1016/s2152-2650(20)30711-4 |
0.328 |
|
| 2019 |
Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. PMID 31628431 DOI: 10.1038/s41375-019-0612-8 |
0.355 |
|
| 2019 |
Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. American Journal of Hematology. PMID 31379016 DOI: 10.1002/Ajh.25605 |
0.324 |
|
| 2019 |
Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 31227358 DOI: 10.1016/j.clml.2019.05.008 |
0.313 |
|
| 2019 |
Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. PMID 31175001 DOI: 10.1016/S1470-2045(19)30150-0 |
0.349 |
|
| 2019 |
Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 31055076 DOI: 10.1016/J.Nano.2019.04.007 |
0.386 |
|
| 2019 |
Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology. PMID 30945331 DOI: 10.1002/ajh.25484 |
0.504 |
|
| 2019 |
DeAngelo DJ, Erba HP, Jonas BA, O'Dwyer M, Marlton P, Huls GA, Liesveld J, Cooper BW, Bhatnagar B, Armstrong M, Fogler W, Chen M, Magnani J, Thackray HM, Advani AS, et al. A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 37: TPS7066-TPS7066. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS7066 |
0.302 |
|
| 2019 |
Pham B, Hoeg R, Hariharan N, Alvarez K, Rosenberg AS, Jonas BA, Tuscano JM, Abedi M. Treatment with FLAG followed by second allogeneic stem cell transplant for relapsed acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology. 37: e18503-e18503. DOI: 10.1200/JCO.2019.37.15_SUPPL.E18503 |
0.381 |
|
| 2019 |
Odenike O, Wolff JE, Borthakur G, Aldoss IT, Rizzieri D, Prebet T, Hu B, Dinh M, Chen X, Modi D, Freise KJ, Jonas BA. Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 37: 7030-7030. DOI: 10.1200/JCO.2019.37.15_SUPPL.7030 |
0.372 |
|
| 2019 |
Poh C, Frankel P, Ruel C, Abedi M, Schwab E, Costello CL, Zain J, Budde LE, William BM, Foss FM, Jonas BA, Rosenberg AS, Newman E, Tuscano J. Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis Blood. 134: 760-760. DOI: 10.1182/Blood-2019-124254 |
0.342 |
|
| 2018 |
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. PMID 30361262 DOI: 10.1182/Blood-2018-08-868752 |
0.334 |
|
| 2018 |
Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute myeloid leukaemia. Journal of Investigative Medicine : the Official Publication of the American Federation For Clinical Research. PMID 30127098 DOI: 10.1136/jim-2018-000807 |
0.336 |
|
| 2018 |
Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM. Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia treated in California. American Journal of Hematology. PMID 30105792 DOI: 10.1002/Ajh.25252 |
0.382 |
|
| 2018 |
Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. PMID 29451695 DOI: 10.1002/cncr.31296 |
0.315 |
|
| 2018 |
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology. PMID 29339097 DOI: 10.1016/S1470-2045(18)30010-X |
0.341 |
|
| 2018 |
Borthakur G, Wolff JE, Aldoss I, Hu B, Dinh M, Torres A, Chen X, Rizzieri D, Sood A, Odenike O, Jonas BA. First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data. Journal of Clinical Oncology. 36: 7019-7019. DOI: 10.1200/JCO.2018.36.15_SUPPL.7019 |
0.314 |
|
| 2018 |
Dinardo CD, Pratz KW, Potluri J, Pullarkat VA, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, Pollyea DA, Letai AG. Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). Journal of Clinical Oncology. 36: 7010-7010. DOI: 10.1200/JCO.2018.36.15_SUPPL.7010 |
0.348 |
|
| 2018 |
Pollyea DA, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, Xu T, Dail M, Chyla B, Potluri J, DiNardo CD. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy Blood. 132: 285-285. DOI: 10.1182/Blood-2018-99-117179 |
0.345 |
|
| 2018 |
Borthakur G, Wolff J, Aldoss I, Hu B, Dinh M, Torres A, Chen X, Rizzieri D, Sood A, Odenike O, Jonas BA. First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data Clinical Lymphoma Myeloma and Leukemia. 18: S203. DOI: 10.1016/J.CLML.2018.07.054 |
0.314 |
|
| 2018 |
DiNardo CD, Pratz K, Potluri J, Pullarkat V, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, Pollyea DA, Letai A. Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 18: S201. DOI: 10.1016/J.Clml.2018.07.050 |
0.349 |
|
| 2017 |
Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer Journal. 7: e605. PMID 28885611 DOI: 10.1038/Bcj.2017.81 |
0.39 |
|
| 2017 |
Jonas BA. On the origin of relapse in AML. Science Translational Medicine. 9. PMID 28701479 DOI: 10.1126/scitranslmed.aan8205 |
0.31 |
|
| 2017 |
Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. British Journal of Haematology. PMID 28419422 DOI: 10.1111/Bjh.14631 |
0.311 |
|
| 2017 |
DeAngelo DJ, Jonas BA, Becker PS, O'Dwyer M, Advani AS, Marlton P, Magnani J, Thackray HM, Liesveld J. GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML. Journal of Clinical Oncology. 35: 2560-2560. DOI: 10.1200/JCO.2017.35.15_SUPPL.2560 |
0.301 |
|
| 2017 |
Jonas BA, Logan AC, Jeyakumar D, Abedi M, Bejar R, Wieduwilt MJ, Oesterich LG, Curtin PT. A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503 Blood. 130: 2973-2973. DOI: 10.1182/Blood.V130.Suppl_1.2973.2973 |
0.301 |
|
| 2017 |
DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian HM, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, et al. Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Blood. 130: 2628-2628. DOI: 10.1182/Blood.V130.Suppl_1.2628.2628 |
0.309 |
|
| 2016 |
Jonas BA, Johnson C, Gratzinger D, Majeti R. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. Plos One. 11: e0159189. PMID 27428079 DOI: 10.1371/Journal.Pone.0159189 |
0.487 |
|
| 2016 |
Moskoff B, Chang A, Ho G, Rosenberg AS, Iannucci A, Jonas BA. Efficacy and Tolerability of Hyper-CVAD in Adult Acute Lymphoblastic Patients: A Retrospective Analysis at a Comprehensive Cancer Center Blood. 128: 5195-5195. DOI: 10.1182/BLOOD.V128.22.5195.5195 |
0.372 |
|
| 2016 |
DeAngelo DJ, Liesveld JL, Jonas BA, O'Dwyer ME, Bixby DL, Magnani JL, Thackray HM, Becker PS. A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date Blood. 128: 4049-4049. DOI: 10.1182/BLOOD.V128.22.4049.4049 |
0.306 |
|
| 2016 |
Datta T, Jonas BA, Rosenberg AS, Li Q, Brunson AM, Ho G, Wun T, Keegan T. Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study Blood. 128: 3982-3982. DOI: 10.1182/Blood.V128.22.3982.3982 |
0.305 |
|
| 2016 |
Ho G, Wun T, Li Q, Brunson AM, Rosenberg AS, Jonas B, Keegan T. Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California Blood. 128: 391-391. DOI: 10.1182/Blood.V128.22.391.391 |
0.377 |
|
| 2016 |
Lin T, Li Y, Zhu Y, Zhang H, Harse R, Lam K, Jonas B, Pan C. Abstract 1313: Targeting micelles eradicate acute myeloid leukemia stem cells in a patient-derived leukemia xenograft model Cancer Research. 76: 1313-1313. DOI: 10.1158/1538-7445.Am2016-1313 |
0.431 |
|
| 2015 |
Ali SF, Sonu RJ, Dwyre DM, Jonas BA, Rashidi HH. Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Reports in Hematology. 2015: 318545. PMID 26798525 DOI: 10.1155/2015/318545 |
0.309 |
|
| 2015 |
Tomlinson BK, Tuscano JM, Abedi M, Welborn J, O'Donnell R, Arora M, Verman R, Jones K, Jonas BA. Phase II trial of the combination of subcutaneous bortezomib (Bortez) and pegylated liposomal doxorubicin (PLD) for the treatment of patients with acute myelogenous leukemia (AML). Journal of Clinical Oncology. 33: 7081-7081. DOI: 10.1200/JCO.2015.33.15_SUPPL.7081 |
0.305 |
|
| 2015 |
DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, Jonas B, Leverson J, Zhu M, Dunbar M, Falotico N, Kirby R, Agarwal S, Mabry M, Potluri J, et al. A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy Blood. 126: 327-327. DOI: 10.1182/Blood.V126.23.327.327 |
0.349 |
|
| 2015 |
Rosenberg AS, Brunson AM, Keegan TH, Jonas B, Tuscano J, Wun T. The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment Blood. 126: 1991-1991. DOI: 10.1182/Blood.V126.23.1991.1991 |
0.38 |
|
| 2015 |
Rosenberg AS, Brunson AM, Keegan TH, Tuscano J, Wun T, Jonas B. Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact Blood. 126: 1305-1305. DOI: 10.1182/Blood.V126.23.1305.1305 |
0.367 |
|
| Show low-probability matches. |